Application of oridonin in preparation of medicine for preventing and / or treating enterovirus infection
By inhibiting CVB3 viral structural protein and RNA loading by lynxylene, the lack of specificity of the treatment of viral myocarditis in the prior art was solved, significantly improved the survival rate of mice and improved viral replication in heart tissue, providing new Antiviral treatment plan.
Patent Information
- Application Number
- CN202410653393.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-24
- Publication Date
- 2024-11-29
Smart Images

Figure CN119033758A_ABST
Abstract
Description
Technical Field
[0001] The invention provides an application of Rubescensine A in preparing a medicine for preventing and / or treating enterovirus infection, and relates to the technical field of biomedicine. Background Art
[0002] Coxsackievirus B Type 3 (CVB3) is a non-capsid positive-strand RNA virus of the Picornaviridae family and is a common enterovirus. It infects the intestines, heart, pancreas, brain, liver, etc. through the fecal-oral route, causing acute and chronic myocarditis, pancreatitis, viral encephalitis, hepatitis, etc. The most common myocarditis is viral myocarditis. Viral myocarditis (VMC) refers to local or diffuse acute and chronic inflammatory lesions of the myocardium caused by viral infection. Among them, CVB3 is the most common pathogen in patients with viral myocarditis. About 25% of patients with viral myocarditis are infected with Coxsackievirus B3. The clinical manifestations of viral myocarditis vary. Non-specific symptoms such as fatigue and shortness of breath or symptoms similar to acute coronary syndrome may occur. Severe cases can cause acute heart damage or chronic persistent heart damage. Viral myocarditis mainly occurs in young and middle-aged patients. It is one of the main causes of heart failure, sudden cardiac death and dilated cardiomyopathy (DCM) in children and young people, accounting for 12% of sudden deaths in patients under 40 years old.
[0003] Oridonin (Ori) is a biologically active n-pentane diterpene and the main active ingredient of Rabdosia rubescens. It is widely used in traditional Chinese medicine and is a common over-the-counter (OTC) herbal medicine. Oridonin has shown considerable anticancer activity, including cell cycle arrest, induction of apoptosis and inhibition of angiogenesis, and has inhibitory effects on a variety of tumor cells. Pharmacological studies have shown that Oridonin can inhibit tumor cell proliferation, inhibit DNA, RNA and protein synthesis of tumor cells, induce apoptosis, and has anti-mutagenic effects. In addition, Oridonin also has a good leading position in the field of medicinal chemistry, because its good stability, suitable molecular weight and drug-like properties ensure its further generation of natural-like compound libraries. Studies have reported that Oridonin has inhibitory effects on herpes simplex virus type 1 (HSV-1) and acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but its role and mechanism in CVB3 virus infection are still unclear, so Oridonin is a promising lead compound to develop new candidate drugs. Summary of the invention
[0004] To solve the above problems, the present invention uses Oridonin extracted from Oridonium rubescens as the research object, and intends to clarify the application of Oridonin Oridonin in the treatment of Coxsackie B virus (CVB3) infection. The experiment of the present invention shows that Oridonin can prevent and / or treat enterovirus infection, and can significantly inhibit the infection of enterovirus in vitro and in vivo, and has a therapeutic effect, wherein the enterovirus is CVB3. The specific technical scheme is as follows:
[0005] The present invention provides the use of Rubescensine A in the preparation of a drug for preventing and / or treating enterovirus infection. The structure of the Rubescensine A is shown in Formula I:
[0006]
[0007] Preferably, the enterovirus is CVB3.
[0008] Preferably, the effective dose of Rubescensine A is 20 mg / kg mouse body weight.
[0009] Preferably, the effective dose of Rubescensine A is 2.0 to 10.0 μM / (1*10 5 cells).
[0010] Preferably, the Rubescensine A is used as a traditional Chinese medicine compound to prepare an inhibitor for the expression of enterovirus structural protein VP1.
[0011] Preferably, the enterovirus is CVB3; the effective dose of Rubescensine A is 2.0 μM, 4.0 μM, 6.0 μM, 10.0 μM (1*10 5 cells).
[0012] Preferably, the Rubescensine A is used as a traditional Chinese medicine compound to prepare an inhibitor to prepare a viral RNA inhibitor in enterovirus-infected cells.
[0013] Preferably, the enterovirus is CVB3; the effective dose of Rubescensine A is 10.0 μM (1*10 5 cells).
[0014] Preferably, the Rubescensine A is used as a traditional Chinese medicine compound to prepare an inhibitor to prepare an inhibitor of green fluorescent protein expressed by enterovirus in enterovirus-infected cells.
[0015] Preferably, the enterovirus is EGFP-CVB3; the effective dose of Rubescensine A is 2.0 μM, 4.0 μM, 6.0 μM, 10.0 μM (1*10 5 In this study, the expression of green fluorescent protein was selected as the detection target of Rubescensine A in inhibiting enterovirus.
[0016] Beneficial effects:
[0017] (1) Oridonin, the active ingredient of Rubescens, was used as the research object to clarify the preventive and therapeutic effects of Oridonin on CVB3 infection. This study found that Oridonin can significantly inhibit CVB3 infection in vivo and in vitro, and has both preventive and therapeutic effects.
[0018] The role of Oridonin in the prevention and / or treatment of enterovirus infections was elucidated, and new applications for existing drug compounds were developed.
[0019] (2) Currently, the treatment of viral myocarditis is non-specific, and there is no more effective antiviral or immunosuppressive therapy. Although immunosuppressive and antiviral treatments continue to emerge, antiviral treatment is currently investigational, and so far, the U.S. Food and Drug Administration has not approved any antiviral drugs for the treatment of myocarditis. Since Rubescensine A has good stability, suitable molecular weight, significant inhibitory effect on CVB3 infection, and no cytotoxicity within a certain dose range, it has good application prospects in the development of drugs for the prevention and treatment of CVB3 infection.
[0020] (3) The results of the study showed that in vivo, Rubescensine A had a significant protective effect on mice infected with CVB3, could improve the survival rate of mice, and could improve myocarditis induced by CVB3. In addition, the expression of CVB3 viral structural protein VP1 in the heart tissue of mice in the Rubescensine A-treated group was significantly reduced. In vitro, Rubescensine A also had a significant protective effect on CVB3-infected cells in CVB3-infected cells, and could improve cell survival rate. At the same time, Rubescensine A has good stability and suitable molecular weight, so it has broad development prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art are briefly introduced below.
[0022] Figure 1 Cytotoxicity assay diagram;
[0023] Figure 2 (1) Treatment schematic diagram, schematic timeline showing the order of oridonin treatment and CVB3 infection; (2) Cytopathic effect diagram. The concentrations of oridonin were 2.0, 4.0, 6.0, and 10 μM. (3) Effect on viral capsid protein, Western blot results showed that oridonin inhibited the expression of viral VP1 protein. (4) Grayscale value statistics were performed using Image J, and quantification was performed using the ratio of VP1 / α-Tubulin;
[0024] Figure 3 shows (1) a schematic diagram of pretreatment, with a timeline showing the order of Rubescensine A pretreatment and CVB3 infection. (2) the effect on viral capsid protein, with Western blot results showing that pretreatment with Rubescensine A inhibited the expression of viral VP1 protein. (3) grayscale value statistics were performed using Image J, and the VP1 / α-Tubulin ratio was used for quantification;
[0025] Figure 4 The QPCR results showed that Rubescensine A inhibited the load of viral RNA at a concentration of 10 μM.
[0026] Figure 5 The results showed that Rubescensine A inhibited the expression of green fluorescent protein by the enterovirus EGFP-CVB3 carrying green fluorescent protein in a dose-dependent manner.
[0027] FIG6 shows the results of the pharmacodynamic evaluation; wherein FIG6(1) shows the changes in survival rate; FIG6(2) shows the changes in body weight;
[0028] Figure 7 shows (1) Western blot showing the expression of VP1, a structural protein of CVB3 virus, in heart tissue. (2) Grayscale value statistics were performed using Image J, and the VP1 / α-Tubulin ratio was used for quantification;
[0029] Figure 8 shows (1) histopathological effects; cardiac tissue photographed under a 10x microscope. (2) histopathological scoring statistics;
[0030] Fig. 9 The QPCR results show the expression of related inflammatory factors in heart tissue after CVB3 infection and oridonin administration. DETAILED DESCRIPTION
[0031] The technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments in the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.
[0032] Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein may be applied to the present invention. The preferred implementation methods and materials described herein are for demonstration purposes only and are not intended to limit the content of this application.
[0033] The experimental methods in the following examples are conventional methods unless otherwise specified, and the experimental materials used in the following examples are purchased from commercial channels unless otherwise specified.
[0034] Experimental cells: Hela cells
[0035] The present invention will be further described below in conjunction with embodiments:
[0036] Example 1 Cytotoxicity Experiment of Rubescensine A
[0037] This experiment was analyzed by CCK8 experiment. In order to determine whether Rubescensine A has an effect on cell viability, Hela cells in the logarithmic growth phase were evenly plated in 96-well plates, with approximately 1×10 cells per well. 4 , cultured in a 37°C incubator until the cells were completely attached, and Rubescensine A was added to each well at 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 15.0, and 20.0 μM using DMEM culture medium containing 2% FBS. An equal volume of PBS was added to the negative control wells, and gently mixed. Six replicate wells were set for each concentration. After culturing at 37°C for 24 h, the culture medium was discarded, and serum-free DMEM culture medium containing 10% CCK-8 was prepared, and 100 μL was added to each well in the form of liquid replacement. After 10-20 min, the absorbance value of each well was detected at 450 nm.
[0038] Cell viability (cell viability%) = OD value of test well / OD value of control well × 100%
[0039] The cytotoxicity experiment of Rubescensine A showed that in the concentration gradient range of 0.5 to 20.0 μM, Rubescensine A had no toxic effect on Hela cells compared with the negative control group. In the subsequent experiments, this study selected a safe concentration range.
[0040] Example 2 Rubescensine A inhibits cytopathic effect caused by CVB3 infection
[0041] Hela cells will produce obvious cytopathic effect (CPE) after infection with CVB3. Therefore, we tested the effect of Rubescensine A on the cytopathic effect caused by CVB3 infection. Hela cells in the logarithmic growth phase were evenly plated in a 24-well plate, with approximately 1×10 cells per well. 5When the cells were attached and the density was about 80%, DMEM containing 2% FBS was added in the form of liquid change, and then CVB3 (MOI = 0.5) was infected and gently mixed. After culturing at 37°C for 1 h, DMEM containing 2% FBS was replaced and oridonin A (2.0, 4.0, 6.0, 10.0 μM) was added to each well, and gently mixed. After culturing at 37°C for 24 h, the cell pathological changes were observed under an inverted fluorescence microscope and pictures were collected.
[0042] The results of cytopathic effect showed that compared with the uninfected Sham group, the PBS group after CVB3 infection had obvious cytopathic effect, and the CPE value was about 70%. Compared with the PBS group, the addition of oridonin treatment could significantly improve the cytopathic effect caused by CVB3 infection. The above results showed that oridonin could inhibit the cytopathic effect caused by CVB3 infected cells.
[0043] Example 3 Rubescensine A significantly inhibits the replication of CVB3 virus in Hela cells
[0044] Hela cells in the logarithmic growth phase were evenly plated in a 24-well plate, with the number of cells per well being approximately 1×10 5 , cultured in a 37°C incubator until the cells were completely attached, replaced with DMEM medium containing 2% FBS, then added CVB3 for infection (MOI = 0.5), gently shaken, cultured at 37°C for 1 h, changed the medium according to the concentration gradient and added 4.0, 6.0, 8.0, 10.0 μM oridonin or an equal volume of PBS to each well, mixed gently, and cultured at 37°C for 24 h, and the VP1 protein expression level was detected by Western blot.
[0045] Western blot results showed that Rubescensine A could significantly reduce the expression of VP1, a structural protein of CVB in Hela cells, showing a dose-dependent effect at 2.0, 4.0, 6.0, and 10.0 μM, and the differences were statistically significant compared with the control group (P < 0.05).
[0046] Example 4 Pretreatment with Rubescensine A can significantly inhibit the replication of CVB3 virus in Hela cells
[0047] Hela cells in the logarithmic growth phase were evenly plated in a 24-well plate, with the number of cells per well being approximately 1×10 5, cultured in a 37°C incubator until the cells were completely attached, replaced with DMEM medium containing 2% FBS by changing the medium, 2.0, 4.0, 6.0, 10.0 μM of oridonin or an equal volume of PBS was added to each well, gently shaken, and cultured at 37°C for 12 h. Then, the medium was replaced with DMEM medium containing 2% FBS by changing the medium, and then infected with CVB3 (MOI = 0.5). After cultured at 37°C for 1 h, the virus was eluted and cultured at 37°C for another 12 h. The expression level of VP1 protein was detected by Western blot.
[0048] Western blot results showed that pretreatment with Rubescensine A could significantly reduce the expression of VP1, a structural protein of CVB3 in Hela cells, showing a dose-dependent effect at 2.0, 4.0, 6.0, and 8.0 μM, and the differences were statistically significant compared with the control group (P < 0.05).
[0049] Example 5 Rubescensine A can inhibit the loading of CVB3 at the RNA level
[0050] Hela cells in the logarithmic growth phase were evenly plated in a 12-well plate, with the number of cells per well being approximately 1×10 6 , cultured in a 37°C incubator until the cells were completely attached, replaced with DMEM medium containing 2% FBS, and then added CVB3 for infection (MOI = 0.5), gently shaken, and cultured at 37°C for 1 h, replaced with 10.0 μM oridonin or an equal volume of PBS, gently mixed, and cultured at 37°C for 24 h. Total cell RNA was extracted by the Trizol method, and then cDNA was obtained by the CVB3-specific reversal procedure and then the RNA level of CVB3 was detected by quantitative PCR.
[0051] Q-PCR results showed that Rubescensine A could significantly reduce the RNA level of CVB3 in Hela cells, and the difference was statistically significant compared with the control group (P<0.05).
[0052] Example 6 Oridonin significantly inhibited the expression of green fluorescence of EGFP-CVB3 virus in Hela cells.
[0053] Hela cells in the logarithmic growth phase were evenly plated in a 24-well plate, with the number of cells per well being approximately 1×10 5, cultured in a 37°C incubator until the cells were completely attached, replaced with DMEM medium containing 2% FBS, and then added EGFP-CVB3 for infection (MOI=1.5), gently shaken, and cultured at 37°C for 1 h. The medium was changed according to the concentration gradient and 4.0, 6.0, 8.0, and 10.0 μM of oridonin or an equal volume of PBS were added to each well, mixed gently, and cultured at 37°C for 24 h. The expression level of green fluorescent protein was observed using an inverted fluorescence microscope.
[0054] Fluorescence observation results showed that Rubescensine A could significantly reduce the expression of green fluorescent protein of EGFP-CVB3 in Hela cells, and exhibited a dose-dependent effect at 4.0, 6.0, 8.0, and 10.0 μM. The above results showed that Rubescensine A could significantly inhibit the replication of CVB3 in Hela cells, and had a dose-dependent effect.
[0055] Example 7 Oridonin can treat CVB3 infection in Balb / C mice
[0056] The 6-8 week old mice were divided into three groups: negative control group: no virus infection group; virus group: virus infection by intraperitoneal injection at TCID50=1000; Rubescensine A experimental group: 24 hours after virus infection, Rubescensine A was intraperitoneally injected once at a dose of 20 mg / kg. (The day of intraperitoneal injection of CVB3 virus infection was recorded as day 0). After infection with CVB3 virus, the death of mice, weight change, exercise capacity, physiological state, etc. were recorded every day. On the 7th day of virus infection, the mice were decapitated and blood was collected.
[0057] The mortality rate and weight change rate of mice within 7 days showed that in the virus group, mice lost significant weight and some died, while the injection of Rubescensine A in the experimental group slowed down the weight loss of mice and the survival rate reached 100%. The above results show that Rubescensine A has a significant protective effect on CVB3-infected mice.
[0058] Example 8 Western blot detection of the expression of VP1 of CVB3 in cardiac tissue
[0059] Western blot was performed on mouse heart tissues from the negative control group, virus group, and Rubescensine A experimental group. The results showed that the expression of VP1 in the heart tissue of mice treated with Rubescensine A was significantly lower than that in the virus group, indicating that Rubescensine A can reduce the replication of the virus in the heart tissue after CVB3 infection.
[0060] Example 9 Histopathological sections
[0061] The heart tissues of mice in each group were fixed in 4% paraformaldehyde for 48 hours, then embedded in paraffin. The mouse heart tissue sections were dried in an oven at 60°C for 1-2 hours and then immersed in xylene for dewaxing; then gradient ethanol (anhydrous ethanol → 95% ethanol → 90% ethanol → 80% ethanol), each gradient was immersed for 5 minutes; washed once with distilled water, erythrin for 5 minutes; washed once with water; subjected to hydrochloric acid ethanol for 1-3 seconds; 55°C water bath anti-blue for 5 minutes; washed once with water; eosin staining for 40 seconds; gradient ethanol (anhydrous ethanol → 95% ethanol → 80% ethanol), each gradient for 2 seconds. Then dried and sealed with neutral quick-drying glue, and observed with an upright fluorescence microscope
[0062] Effect on histopathology: The local inflammatory infiltration in the heart tissue of mice in the CVB3 group was obvious, while the inflammatory infiltration in the experimental group administered with oridonin was reduced.
[0063] Example 10 QPCR detection of inflammatory cytokines in cardiac tissue
[0064] The heart tissues of mice in the negative control group, virus group, and oridonin experimental group were respectively extracted with the Trizol method and RNA was reversed into cDNA, and IL-6, IL-1β, TNF-α, and CXCL-1 were detected by quantitative PCR. The results showed that the RNA level of inflammatory factors in the heart tissue of mice treated with oridonin was significantly lower than that in the virus group, indicating that oridonin can reduce local inflammation of heart tissue after CVB3 infection.
[0065] in conclusion:
[0066] The results of in vivo cytotoxicity experiments showed that in Hela cells, the concentration gradient of 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 15, and 20 μM of oridonin was set for 24 hours, and CCK8 was used to detect the toxic effect of oridonin on cells. This study found that at a concentration of 20 μM oridonin, compared with the negative control group (PBS group), oridonin had no toxic effect on Hela cells. Western Blot results showed that the expression of the structural protein VP1 of enterovirus CVB3 in the oridonin-treated group was significantly lower than that in the PBS group, and was dose-dependent, and there was a statistical difference. Western Blot results showed that the expression of the structural protein VP1 of enterovirus CVB3 in the oridonin-pretreated group was significantly lower than that in the PBS group, and was dose-dependent, and there was a statistical difference. The results of the determination of viral fluorescent protein showed that the green fluorescent protein expressed by the virus in the oridonin-treated group was significantly reduced compared with the EGFP-CVB3 infection group. The cytopathic effect result graph shows that CVB3 infection can cause obvious cell death, with a CPE value of about 70%. The group treated with oridonin can significantly alleviate the cytopathic effect caused by enterovirus CVB3 infection. The results of in vivo pharmacodynamic experiments showed that mice in the CVB3 virus infection group showed slow movement, weight loss, reduced food intake and even death within 4-7 days after infection. For mice in the oridonin injection group, the above symptoms were significantly alleviated, and there was no death. The above results show that oridonin has a significant protective effect on mice infected with CVB3, reducing the weight loss of mice caused by CVB3 virus infection, local inflammation of the heart, etc., and improving the survival rate of mice.
[0067] In summary, the research of the present invention can determine that Oridonin can inhibit the pathological changes caused by enterovirus (CVB3) infection and can be used to prepare drugs for preventing and / or treating enterovirus infection.
[0068] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
[0069] The present invention and its implementation methods are described above, but such description is not restrictive. The drawings are only related to the implementation methods of the present invention, and the actual application is not limited thereto. In short, if ordinary technicians in the field are inspired by it and design methods and embodiments similar to the technical solution without creativity without departing from the purpose of the invention, they should all fall within the scope of protection of the present invention.
Claims
1. Use of Rubescensine A in the preparation of a drug for preventing and / or treating enterovirus infection, Features: The structure of Rubescensine A is shown in Formula I:
2. Use of Rubescensine A according to claim 1 in the preparation of a drug for preventing and / or treating enterovirus infection, Features: The enterovirus is CVB3.
3. Use of Rubescensine A according to claim 2 in the preparation of a drug for preventing and / or treating enterovirus infection, Features: The effective dose of Rubescensine A is 20 mg / kg mouse body weight.
4. Use of Rubescensine A according to claim 2 in the preparation of a drug for preventing and / or treating enterovirus infection, Features: The effective dose of Rubescensine A is 2.0 to 10.0 μM / (1*10 5 cells).
5. Use of Rubescensine A according to claim 1 in the preparation of a drug for preventing and / or treating enterovirus infection, Features: The oridonin is used as a traditional Chinese medicine compound to prepare an inhibitor for preparing an inhibitor of the expression of enterovirus structural protein VP1.
6. Use of Rubescensine A according to claim 5 in the preparation of a drug for preventing and / or treating enterovirus infection, Features: The enterovirus is CVB3; the effective dose of Rubescensine A is 2.0 μM, 4.0 μM, 6.0 μM, 10.0 μM (1*10 5 cells).
7. Use of Rubescensine A according to claim 1 in the preparation of a drug for preventing and / or treating enterovirus infection, Features: The oridonin is used as a traditional Chinese medicine compound to prepare an inhibitor to prepare a viral RNA inhibitor in enterovirus-infected cells.
8. Use of Rubescensine A according to claim 7 in the preparation of a drug for preventing and / or treating enterovirus infection, Features: The enterovirus is CVB3; the effective dose of Rubescensine A is 10.0 μM (1*10 5 cells).
9. Use of Rubescensine A according to claim 1 in the preparation of a drug for preventing and / or treating enterovirus infection, Features: The oridonin is used as a traditional Chinese medicine compound to prepare an inhibitor to prepare an inhibitor of green fluorescent protein expressed by enterovirus in enterovirus-infected cells.
10. Use of Rubescensine A according to claim 9 in the preparation of a drug for preventing and / or treating enterovirus infection, Features: The enterovirus is EGFP-CVB3; the effective dose of Rubescensine A is 2.0 μM, 4.0 μM, 6.0 μM, 10.0 μM (1*10 5 cells).
Citation Information
Patent Citations
Application of oridonin in preparing drugs for preventing or treating NLRP3 inflammasome-related diseases
CN110151749A
Methods of using andrographolide, oridonin and isoliquiritigenin and derivatives thereof
US20230069586A1
Use of rubescensine a and derivatives thereof in pharmacy
WO2008022505A1
